BTC 
ETH 
XRP
SOL 
DOGE - This topic is empty.
-
Posts
-
Published: October 4, 2026 | Stock Picks
The thesis
Johnson & Johnson just put up a clean Q2 beat, raised its full-year guidance, and is marching toward its first-ever $100 billion revenue year — and the market’s response has been to knock the stock down 8.9% from its September high to $256.03. The stock now sits between its 50-day and 200-day moving averages with an RSI near oversold territory, a 2.09% dividend yield, and a consensus price target implying roughly 7% upside.
With Q3 earnings due October 13 and the two-year Icotyde psoriasis data landing October 2, this is a discounted-quality entry into healthcare’s most durable blue chip.
Business snapshot: the medicine chest of the American healthcare system
Johnson & Johnson develops and manufactures prescription medicines and medical technologies through two segments: Innovative Medicine and MedTech. Its portfolio spans immunology, oncology, neuroscience, cardiovascular care, surgical devices, orthopedics, and vision care — products sold to patients, hospitals, and healthcare professionals in markets around the world.
The moat is depth and diversification. J&J has run this playbook for 140 years: blockbuster franchises (Darzalex, Tremfya) layer over newer growth engines (Spravato, Caplyta, Icotyde) while MedTech compounds quietly in the background. Even as Stelara bleeds to biosimilar competition, the underlying portfolio is expanding at a double-digit rate once you strip out that known headwind. The company spun off its consumer-health business as Kenvue in 2023, leaving a focused pharma-and-medtech machine led by Chairman and CEO Joaquin Duato.
Financials: what the numbers say
The second quarter of 2026 (reported in July) showed a portfolio that is quietly accelerating under the surface:
- Worldwide sales: $25.31 billion, up 6.6% year over year and ahead of the ~$25.06 billion consensus. On an operational basis, sales grew 5.6% — but management disclosed that Stelara biosimilar competition created a 460-basis-point drag on reported growth, meaning the underlying business is expanding at a double-digit clip.
- Adjusted diluted EPS: $2.90, up 4.7% year over year and above the ~$2.84 consensus. GAAP diluted EPS was $2.27 on $5.5 billion of net earnings.
- Innovative Medicine: $16.38 billion, up 7.8% year over year. Oncology surged 17.3% to $7.41 billion.
- Darzalex: $4.21 billion, up 18.9%; Tremfya: $2.05 billion, up 72.5% — the two franchises absorbing the Stelara falloff. Stelara: $740 million, down 55.2% as biosimilar erosion ran its course.
- MedTech: $8.9 billion, up 3.6% on an operational basis — steady compounding from the devices business.
- Guidance raised: full-year operational sales growth of 6.5%–7.1%, with a midpoint of roughly $100.6 billion in sales, and adjusted EPS of about $11.50–$11.65. That would be J&J’s first $100 billion revenue year.
- Management also outlined $21 billion of 2026 free cash flow at the Deutsche Bank Healthcare Summit on September 17, alongside the raised outlook.
(Related reading: UnitedHealth (UNH) Stock Analysis: A Buy at $376 as the Turnaround Gains Steam and Eli Lilly (LLY) Stock: JPMorgan Sees $1,500 — Buy the Pullback at $1,157)
Chart & technicals: pullback into the support zone
J&J closed Friday at $256.03, down 1.02% on the day and 6.97% over the past 30 days — yet still up 37.7% over the last 12 months. The 52-week high of $281.07 was printed on September 2; the stock is now 8.9% below it.
The chart structure, with real numbers:
- 50-day moving average: ~$266 — overhead, and the first resistance the stock must reclaim. It coincides with a 50-day trading range of $254.54–$278.66.
- 200-day moving average: ~$241.50 — the rising long-term support line. The stock is drifting toward it, not away from it.
- Resistance: ~$264.50, then the 50-day near $266. A close back above $266 would be the first real repair signal.
- Support: the 200-day at ~$241.50, then the 52-week low of $182.94 far below.
- RSI (14-day): ~35 — near oversold, the weakest momentum reading in months.
- Volume: 10.25 million shares Friday vs. a 6.04-million average — elevated selling volume that reads like a washout day rather than orderly distribution.
Valuation: 22x forward earnings for healthcare’s quality leader
At $256, J&J trades at 29.7x trailing earnings — but that figure is backward-looking and includes the Stelara patent-cliff trough. Against the raised full-year guidance of roughly $11.60 per share, the stock is about 22x forward earnings — a meaningful derating from the trailing multiple.
The dividend yield has widened to 2.09% as the price fell, which is real income while you wait for the turnaround math to compound. Analyst consensus is Moderate Buy with an average 12-month target of $274.13 across 25 analysts (as of September 29) — about 7% upside from Friday’s close.
The tape of analyst moves leans constructive: UBS reaffirmed Buy on September 22; TD Cowen raised its target from $250 to $300 on July 13; Wells Fargo lifted its target to $282 on August 3; and on September 29 BofA raised its target from $263 to $278, nearly doubling its peak-sales forecast for the Icotyde oral psoriasis drug to $4.5 billion.
Catalysts & what to watch
- Q3 2026 earnings: October 13, before the market opens. The single most important near-term event. One caution flag: BofA projects Q3 EPS of just $2.53 vs. the ~$2.87 consensus, citing research costs tied to recent deals — a setup where a modest beat could re-rate the stock.
- Icotyde two-year data (October 2): 70% of psoriasis patients had clear or almost-clear skin at week 112, up from 57% at week 16 — durability data that underpins BofA’s raised $4.5 billion peak-sales estimate.
- The $100 billion milestone: if Q3 confirms the trajectory, J&J cements its first-ever $100B revenue year — a psychological and fundamental re-rating event.
- Stelara drag fading: every quarter, the biosimilar headwind gets closer to annualizing, and the underlying double-digit portfolio growth starts showing up in the headline number.
Risks — honestly stated
- The Stelara cliff isn’t done. A 55.2% collapse to $740 million is steep, and if biosimilar erosion deepens further, the 460-bps drag persists and the headline growth story stalls.
- Q3 could genuinely miss. BofA’s $2.53 EPS estimate sits well below the $2.87 consensus — deal-related R&D costs are real, and an earnings miss next week would likely break the 200-day support.
- 29.7x trailing P/E is full for 6.6% growth. The forward multiple is more reasonable, but if growth decelerates, the “quality premium” compresses fast.
- The chart is still falling. RSI near 35 can get to 30 before it bottoms. There’s no confirmed reversal yet — this is a scale-in-the-support-zone entry, not a breakout chase.
Bottom line
Johnson & Johnson is a 140-year-old compounding machine having its best operational year in memory — a Q2 beat, raised guidance, a $21 billion free-cash-flow target, and a portfolio growing double digits beneath the Stelara noise. At $256, you’re buying it 9% off its high, near oversold, with a 2.09% dividend and Q3 earnings in nine days. For the 6–18 month horizon, this is the kind of discounted quality I would put my own money into today.
Sources:
- https://www.financecharts.com/stocks/JNJ/summary/price
- https://www.marketbeat.com/stocks/NYSE/JNJ/?Vote=0
- https://www.ad-hoc-news.de/boerse/corporate-news/johnson-and-johnson-stock-reports-durable-psoriasis-data-from-icotyde/70224208
- https://www.ad-hoc-news.de/boerse/corporate-news/bofa-raises-target-for-johnson-and-johnson-stock-from-usd-263-to-usd-278/70216456
- https://tickeron.com/earnings/JNJ/
- https://www.ad-hoc-news.de/boerse/corporate-news/johnson-and-johnson-stock-draws-a-moderate-buy-consensus/70198735
- https://www.ad-hoc-news.de/boerse/corporate-news/johnson-and-johnson-stock-follows-raised-2026-guidance/70183369
- https://pandaforecast.com/stock_forecasts/forecast_jnj/
Auto-posted by the Bull Lounge research desk.
Not financial advice. Do your own research.
Discussion: With Q3 earnings arriving October 13, would you buy JNJ here at $256 — or wait to see whether it tests the 200-day moving average near $241 first?
Log in to vote
